Rezolute: Clinical Trials

2 trials sponsored by Rezolute, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 recruiting. 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 32Active not recruiting 1, Recruiting 1

Follow Rezolute: new trials by email

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
Ersodetug - Tumor Hyperinsulinism (Tumor HI)
Phase 3RecruitingRezolute162025-04-162026-09-28
RZ358 Treatment for Congenital Hyperinsulinism
RZ358 (5 mg/kg) + SOC (Standard-of-Care) or Placebo + SOC, RZ358 (10 mg/kg) or Placebo + SOC, RZ358 (5-10 mg/kg) + SOC - Congenital Hyperinsulinism
Phase 3Active not recruitingRezolute562024-01-112026-01-08

Conditions studied

Hyperinsulinism (2)  ·  Hypoglycemia (2)  ·  Adenoma, Islet Cell (1)  ·  Congenital Hyperinsulinism (1)  ·  Digestive System Diseases (1)  ·  Fibrosarcoma (1)  ·  Glucose Metabolism Disorders (1)  ·  Insulinoma (1)  ·  Liposarcoma (1)  ·  Metabolic Diseases (1)  ·  Neoplasms (1)  ·  Neuroectodermal Tumors, Primitive (1)  ·  Neuroendocrine Tumors (1)  ·  Pancreatic Diseases (1)

Interventions

Standard of Care (1)

Countries

France (2)  ·  United Kingdom (2)  ·  United States (2)  ·  Bulgaria (1)  ·  Denmark (1)  ·  Georgia (1)  ·  Germany (1)  ·  Greece (1)  ·  Netherlands (1)  ·  Oman (1)  ·  Qatar (1)  ·  Spain (1)  ·  Switzerland (1)  ·  Turkey (Türkiye) (1)  ·  Vietnam (1)

Top investigators

Gopal Saha, MD (1)